Transformed yeast system for developing therapeutic hybrid protein drug by site-specific modification

摘要

PURPOSE: A transformed yeast system for developing fusion glycoproteins by a site-specific modification method is provided, thereby cheaply mass producing the fusion glycoproteins having improved medical activity and titer. CONSTITUTION: Transformed yeast Saccharomyces cerevisiae MPY(KCCM-10441) has no genes which are related to the addition of sugar chain, such as OCH1(SEQ ID NO: 1), ANP1(SEQ ID NO: 2), MNN11(SEQ ID NO: 3), HOC1(SEQ ID NO: 4) and MNN2(SEQ ID NO: 5), for expression of partially sugar chain removed glycoproteins. The glycoproteins are produced by using the transformed yeast Saccharomyces cerevisiae MPY(KCCM-10441), wherein the sugar comprises N-acethylglucosamine; and the glycoproteins are -, -, and -interferon, asparaginase, arginase, adenosine deaminase, superoxide dismutase, catalase, lipase, adenosine diphosphatase, thyrosinase, glucose oxidase, glucosidase, blood factor VII, VIII and IX, immunoglobulin, cytokines, interleukins, granulocyte colony stimulating factor and granulocyte macrophage colony.